SC-43
SC-43 Basic information
- Product Name:
- SC-43
- Synonyms:
-
- 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(3-(4-cyanophenoxy)phenyl)urea
- SC-43
- Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[3-(4-cyanophenoxy)phenyl]-
- antiproliferative,Inhibitor,SC-43,SHP-1,PTPN6,Phosphatase,Apoptosis,caspase-3,SC 43,anti-fibrotic,p-STAT3,anticancer,orally,SC43,PARP,STAT,inhibit
- CAS:
- 1400989-25-4
- MF:
- C21H13ClF3N3O2
- MW:
- 431.8
- Mol File:
- 1400989-25-4.mol
SC-43 Chemical Properties
- Boiling point:
- 462.0±45.0 °C(Predicted)
- Density
- 1.46±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- DMSO: 250 mg/mL (578.97 mM)
- form
- A solid
- pka
- 12.92±0.70(Predicted)
- color
- White to off-white
SC-43 Usage And Synthesis
Biological Activity
SC-43 is a derivative of sorafenib, an agonist of Src-homology protein tyrosine phosphatase-1 (SHP-1/PTPN6), which reduces liver fibrosis. SC-43 can reduce p-STAT3 and induce apoptosis, and has antitumor activity.
in vitro
SC-43 (0-10 μM; 24-72 hours; HuCCT-1, KKU-100, and CGCCA cells) treatment reveals the anti-proliferative effects in cholangiocarcinoma (CCA) cell lines in a dose-dependent manner after treating 24, 48 and 72 hours respectively.
Its treatment shows increased sub-G1 cells and G2-M arrest, indicating SC-43 induced differential apoptotic effects in these cell lines.
Its (0-10 μM; 24 hours; HuCCT-1, KKU-100, and CGCCA cells) treatment demonstrates significant increase in cleaved caspase-3 and PARP level.
Its activates SH2 domain-containing phosphatase 1 (SHP-1) activity, leading to p-STAT3 and downstream cyclin B1 and Cdc2 downregulation. Its augments SHP-1 activity by direct binding to N-SH2 and relief of its autoinhibition.
Cell Cycle Analysis
Cell Line: | HuCCT-1, KKU-100, and CGCCA cells |
Concentration: | 0 μM, 1 μM, 2.5 μM, 5 μM, 10 μM |
Incubation Time: | 24 hours |
Result: | Showed increased sub-G1 cells and G2-M arrest. |
Western Blot Analysis
Cell Line: | HuCCT-1, KKU-100, and CGCCA cells |
Concentration: | 0 μM, 1 μM, 2.5 μM, 5 μM, 10 μM |
Incubation Time: | 24 hours |
Result: | Demonstrated significant increase in cleaved caspase-3 and PARP level. |
in vivo
SC-43 (10-30 mg/kg; oral gavage; daily; for 23 days; male NCr athymic nude mice) treatment exhibits xenograft tumor growth inhibition, p-STAT3 reduction and SHP-1 activity elevation.
Animal Model: | Male NCr athymic nude mice (5-7 weeks of age) injected with HuCCT-1 cells |
Dosage: | 10 mg/kg or 30 mg/kg |
Administration: | Oral gavage; daily; for 23 days |
Result: | Exhibited xenograft tumor growth inhibition, p-STAT3 reduction and SHP-1 activity elevation. |
target
Target | Value |
SHP-1 () | |
STAT3 () |
SC-43Supplier
- Tel
- 18344585702
- 550795326@qq.com
- Tel
- 021-52996696,15000506266 15000506266
- Tel
- 021-51619050 13301662590
- mandy@atkchemical.com
- Tel
- 021-65675885 18964387627
- info@efebio.com
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com